Qingchen Zhu, Guiheng Zhang, Ming Cao, Huan Huang, Dan He, Zhongsheng Zang, Jing Xing, Ming Zhan, Siyu Pei, Xiuyu Deng, Juan Li, Guangxun Meng, Jing Xu, Dongfang Dai, Guohong Hu, Mingyue Zheng, Chenli Liu, Jun Qin, Yichuan Xiao
{"title":"Microbiota-shaped neutrophil senescence regulates sexual dimorphism in bladder cancer","authors":"Qingchen Zhu, Guiheng Zhang, Ming Cao, Huan Huang, Dan He, Zhongsheng Zang, Jing Xing, Ming Zhan, Siyu Pei, Xiuyu Deng, Juan Li, Guangxun Meng, Jing Xu, Dongfang Dai, Guohong Hu, Mingyue Zheng, Chenli Liu, Jun Qin, Yichuan Xiao","doi":"10.1038/s41590-025-02126-6","DOIUrl":null,"url":null,"abstract":"<p>Sex disparities have been epidemiologically demonstrated in non-reproductive cancers, yet how the sex-specific intrinsic microbiome orchestrates the immune system to affect these disparities is unclear. Here we identify a subpopulation of RETNLG<sup>+</sup>LCN2<sup>+</sup> senescence-like neutrophils (RLSNs) that preferentially accumulate in the male tumor microenvironment and exert a strong immunosuppressive effect to limit antitumor immunity, resulting in poor prognosis for patients with bladder cancer. This difference in enrichment of RLSNs between sexes can be attributed to intestinal bacterium <i>Alistipes shahii</i>, which preferentially populates in females rather than males. <i>A. shahii</i>-associated metabolite lurasidone directly targets iron sequestrator LCN2 in RLSNs. By freeing Fe<sup>2+</sup>, lurasidone induces ferroptosis, thereby eliminating RLSNs and promoting antitumor immunity in females. In males lacking <i>A. shahii</i> and lurasidone, RLSNs have a survival advantage. Together, these findings demonstrate that a microbiota–lurasidone–LCN2 circuit regulates sexual disparity in bladder cancer and indicates the therapeutic potential of lurasidone for male cancer patients.</p>","PeriodicalId":19032,"journal":{"name":"Nature Immunology","volume":"35 1","pages":""},"PeriodicalIF":27.7000,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41590-025-02126-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Sex disparities have been epidemiologically demonstrated in non-reproductive cancers, yet how the sex-specific intrinsic microbiome orchestrates the immune system to affect these disparities is unclear. Here we identify a subpopulation of RETNLG+LCN2+ senescence-like neutrophils (RLSNs) that preferentially accumulate in the male tumor microenvironment and exert a strong immunosuppressive effect to limit antitumor immunity, resulting in poor prognosis for patients with bladder cancer. This difference in enrichment of RLSNs between sexes can be attributed to intestinal bacterium Alistipes shahii, which preferentially populates in females rather than males. A. shahii-associated metabolite lurasidone directly targets iron sequestrator LCN2 in RLSNs. By freeing Fe2+, lurasidone induces ferroptosis, thereby eliminating RLSNs and promoting antitumor immunity in females. In males lacking A. shahii and lurasidone, RLSNs have a survival advantage. Together, these findings demonstrate that a microbiota–lurasidone–LCN2 circuit regulates sexual disparity in bladder cancer and indicates the therapeutic potential of lurasidone for male cancer patients.
期刊介绍:
Nature Immunology is a monthly journal that publishes the highest quality research in all areas of immunology. The editorial decisions are made by a team of full-time professional editors. The journal prioritizes work that provides translational and/or fundamental insight into the workings of the immune system. It covers a wide range of topics including innate immunity and inflammation, development, immune receptors, signaling and apoptosis, antigen presentation, gene regulation and recombination, cellular and systemic immunity, vaccines, immune tolerance, autoimmunity, tumor immunology, and microbial immunopathology. In addition to publishing significant original research, Nature Immunology also includes comments, News and Views, research highlights, matters arising from readers, and reviews of the literature. The journal serves as a major conduit of top-quality information for the immunology community.